The goal of this study is to evaluate the safety of the study drug PTC596 (Unesbulin) taken in combination with radiotherapy (RT) when given to pediatric patients newly diagnosed with High-Grade Glioma (HGG) including diffuse intrinsic pontine glioma (DIPG). The main aims of the study are to: * Find the safe dose of the study drug PTC596that can be given without causing serious side effects. * Find out the amount of drug that enters blood (in all patients) and tumor (in patients who receive drug prior to a planned surgery for removal of their brain tumor) During the first cycle (6-7weeks), patients will receive drug orally twice a week in combination with daily RT. During subsequent cycles (4 weeks each), they will receive only the study drug orally twice a week. Funding Source - FDA OOPD
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Establish MTD and RP2D of PTC596
Timeframe: At the end of Cycle 1 (42-49 days)
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Timeframe: From Day 1 of treatment through 30 days following end of protocol treatment
Maximum Plasma Concentration [Cmax] of PTC596 (A, B, C, D)
Timeframe: Days1 through 29
Tumor Concentration of PTC596 (B)
Timeframe: Day 4 of surgical cycle
Protein levels of BMI1 in tumor
Timeframe: Day 4 of surgical cycle